Molecular Consequences of the R453C Hypertrophic Cardiomyopathy Mutation on Human Β-Cardiac Myosin Motor Function

Total Page:16

File Type:pdf, Size:1020Kb

Molecular Consequences of the R453C Hypertrophic Cardiomyopathy Mutation on Human Β-Cardiac Myosin Motor Function Molecular consequences of the R453C hypertrophic cardiomyopathy mutation on human β-cardiac myosin motor function Ruth F. Sommesea,1, Jongmin Sunga,b,1, Suman Naga,1, Shirley Suttona, John C. Deaconc, Elizabeth Choea,d, Leslie A. Leinwandc, Kathleen Ruppela,e,2, and James A. Spudicha,2 Departments of aBiochemistry, ePediatrics (Cardiology), and dCancer Biology Program, Stanford University School of Medicine, Stanford, CA 94305; bDepartment of Applied Physics, Stanford University, Stanford, CA 94305; and cBioFrontiers Institute, Department of Molecular, Cellular, and Developmental Biology, University of Colorado, Boulder, CO 80309 Contributed by James A. Spudich, May 19, 2013 (sent for review April 26, 2013) Cardiovascular disorders are the leading cause of morbidity and activity (8). Lowey et al. subsequently showed that the effects of mortality in the developed world, and hypertrophic cardiomyopa- the R403Q mutation in mouse cardiac myosin depended on the thy (HCM) is among the most frequently occurring inherited cardiac isoform into which the mutation was introduced. In α-cardiac disorders. HCM is caused by mutations in the genes encoding the myosin, they saw an increase in both ATPase activity and ve- fundamental force-generating machinery of the cardiac muscle, locity, whereas in the β-cardiac myosin, there was no significant including β-cardiac myosin. Here, we present a biomechanical anal- change in the velocity and actually a slight decrease in the ATPase ysis of the HCM-causing mutation, R453C, in the context of human activity (9). β-cardiac myosin. We found that this mutation causes a ∼30% de- As the R403Q data illustrate, the difficulty in interpreting the crease in the maximum ATPase of the human β-cardiac subfragment effects of these mutations has largely been due to the limited 1, the motor domain of myosin, and a similar percent decrease in the availability of homogeneous and fully active human motor pro- in vitro velocity. The major change in the R453C human β-cardiac teins and the inadequacy of commonly used animal models. Given subfragment 1 is a 50% increase in the intrinsic force of the motor that the HCM mutant phenotype results from single-residue compared with wild type, with no appreciable change in the stroke substitutions in β-MHC, observing the effects of such a mutation BIOCHEMISTRY size, as observed with a dual-beam optical trap. These results predict in a nonhuman protein background where there are many other that the overall force of the ensemble of myosin molecules in the residue differences from the human sequence is far from ideal. muscle should be higher in the R453C mutant compared with wild The majority of animal protein studies are derived from rodent type. Loaded in vitro motility assay confirms that the net force in the models that have a different cardiac MHC isoform composition ensemble is indeed increased. Overall, this study suggests that (predominantly α-MHC instead of β-MHC). Both α- and β-MHC the R453C mutation should result in a hypercontractile state in isoforms from rodents have >30 residue differences compared the heart muscle. with human β-cardiac myosin, and HCM-causing myosin muta- tions in mice have different biochemical effects depending on heart disease | optical trapping | single-molecule force measurements their backbone isoform (9, 10). Until recently, expression of hu- man cardiac muscle myosin has proven recalcitrant to common ypertrophic cardiomyopathy (HCM) is among the most recombinant protein expression methods. Additionally, cardiac Hcommon of inherited cardiovascular disorders, affecting ∼1in biopsies yield limited amounts of enzymatically active motor and 500 individuals (1). HCM is characterized by left ventricular hy- are heterogeneous in the proportion of the mutated form. This pertrophy, cardiomyocyte disarray, and myocardial fibrosis. HCM problem has now been addressed by a recently developed muscle patients typically have left ventricles with small cavities and pre- cell expression system that provides a source of active recombi- β served or even enhanced global systolic function, but impaired nant human -cardiac muscle myosin (11). β relaxation (2). Clinically, HCM is the most common cause of In this study, we have focused on the HCM-causing -cardiac fi β sudden cardiac death in young adults (3). The first genetic cause of myosin mutation R453C, located next to strand ve of the - fi pleated sheet of myosin ∼5 nm from the actin-binding region and familial HCM was identi ed in 1990 (4). Missense mutations in the ∼ Discussion major proteins of the sarcomere have since been identified in HCM 3 nm from the nucleotide-binding site ( ). This muta- patients, and may account for up to 60% of all cases (2). Although tion is considered to be malignant and the small number of a number of these mutations have been studied using a variety of investigations into the functional biochemical and biophysical effects of this mutation have yielded contradictory results (12–14). approaches, there is no clear consensus as to the mechanism(s) by fi which these mutations give rise to the disease state. We have puri ed a Subfragment 1 (S1) construct of human β-cardiac myosin containing a truncated human MHC (residues One of the most commonly mutated genes is myosin heavy – chain 7 or MYH7, which encodes β-cardiac myosin heavy chain 1 808) and the human ventricular essential light chain (ELC) (β-MHC), the major cardiac muscle myosin isoform in the human (Fig. S1), followed by a short linker and a carboxy terminal eGFP heart. In general, HCM resulting from β-MHC mutations are characterized by early onset and severe left ventricular hyper- trophy (5). Although several mutations in β-MHC have been Author contributions: R.F.S., J.S., S.N., K.R., and J.A.S. designed research; R.F.S., J.S., S.N., fi S.S., E.C., and K.R. performed research; J.C.D., E.C., L.A.L., and K.R. contributed new studied over the past 15 y, there has been signi cant disagreement reagents/analytic tools; R.F.S., J.S., S.N., and J.A.S. analyzed data; and R.F.S., J.S., S.N., K.R., in the literature as to the effects of these mutations on the bio- and J.A.S. wrote the paper. chemical and biophysical properties of β-cardiac myosin (reviewed The authors declare no conflict of interest. in ref. 6). For example, the first cardiomyopathy-causing mutation Freely available online through the PNAS open access option. β fi in -cardiac myosin to be identi ed was R403Q. Initial studies on 1R.F.S., J.S., and S.N. contributed equally to this work. this mutant isolated from cardiac and soleus muscle biopsies 2To whom correspondence may be addressed. E-mail: [email protected] or kruppel@ reported a decrease in in vitro sliding velocity (7). Later studies stanford.edu. α using mouse -cardiac myosin containing the R403Q mutation This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10. found an increase in velocity and also an increase in the ATPase 1073/pnas.1309493110/-/DCSupplemental. www.pnas.org/cgi/doi/10.1073/pnas.1309493110 PNAS Early Edition | 1of6 Downloaded by guest on September 26, 2021 moiety (SI Materials and Methods). We refer to this construct as saturating ATP concentration, or the strongly bound state time (ts) simply human β-cardiac S1 throughout. Here we present a de- (Fig. S2). For the R453C mutant and the WT, ts was ∼16 ms. These scription of the effects of this mutation on human β-cardiac S1 values are, however, only estimates given the difficulty of accu- function at both the single-molecule and ensemble levels. Sin- rately detecting and selecting short events in the trap, which are gle-molecule analysis revealed a significant increase in intrinsic challenging to distinguish from Brownian noise of the trapped force of the mutant motor by 50%, such that the net ensemble beads and instrument noise. Hence, a small change in the ts is force is higher than the wild-type (WT) motor, as confirmed by currently difficult to measure with our instrument. a loaded in vitro motility assay. Together, the data support a model whereby heart muscle containing this mutation would R453C Human β-Cardiac S1 Has a Lower Velocity than WT. We mea- be hypercontractile. sured the velocity of motor-driven actin filaments in methylcel- lulose as a function of actin filament length for both WT and Results R453C human β-cardiac S1. The average maximum velocity (vo) − R453C Human β-Cardiac S1 Has a Lower Maximum Actin-Activated for R453C at 23 °C for human β-cardiac S1 (610 ± 30 nm·s 1) −1 ATPase than WT. To measure the maximal rate of ATP turnover was significantly slower than that of WT (800 ± 40 nm·s )(P < (kcat) by the acto–myosin complex, we used an actin-activated 0.0001). The decrease in velocity for R453C compared with WT myosin ATPase assay at 23 °C. The kcat of R453C human was also observed at 30 °C (Fig. 2, Table S1). −1 β-cardiac S1 (5.0 ± 0.2 s ) was significantly lower (30%; P < The maximum velocity vo in the in vitro motility assay is related − 0.0002) than that of the WT motor (7.4 ± 0.4 s 1) (Fig. 1A, Table to the displacement generated by the myosin power stroke (i.e., S1). This difference was also seen with human β-cardiac S1 that the stroke size d) and the duration that myosin remains strongly was freshly recycled by binding to actin in the absence of ATP attached to actin (ts), such that vo= d/ts (15). Besides the estimates and then releasing active heads from the actin in 2 mM ATP (this from the trap measurements, the ts of S1 in saturating ATP process eliminates “dead heads” from the population).
Recommended publications
  • Identification of the Binding Partners for Hspb2 and Cryab Reveals
    Brigham Young University BYU ScholarsArchive Theses and Dissertations 2013-12-12 Identification of the Binding arP tners for HspB2 and CryAB Reveals Myofibril and Mitochondrial Protein Interactions and Non- Redundant Roles for Small Heat Shock Proteins Kelsey Murphey Langston Brigham Young University - Provo Follow this and additional works at: https://scholarsarchive.byu.edu/etd Part of the Microbiology Commons BYU ScholarsArchive Citation Langston, Kelsey Murphey, "Identification of the Binding Partners for HspB2 and CryAB Reveals Myofibril and Mitochondrial Protein Interactions and Non-Redundant Roles for Small Heat Shock Proteins" (2013). Theses and Dissertations. 3822. https://scholarsarchive.byu.edu/etd/3822 This Thesis is brought to you for free and open access by BYU ScholarsArchive. It has been accepted for inclusion in Theses and Dissertations by an authorized administrator of BYU ScholarsArchive. For more information, please contact [email protected], [email protected]. Identification of the Binding Partners for HspB2 and CryAB Reveals Myofibril and Mitochondrial Protein Interactions and Non-Redundant Roles for Small Heat Shock Proteins Kelsey Langston A thesis submitted to the faculty of Brigham Young University in partial fulfillment of the requirements for the degree of Master of Science Julianne H. Grose, Chair William R. McCleary Brian Poole Department of Microbiology and Molecular Biology Brigham Young University December 2013 Copyright © 2013 Kelsey Langston All Rights Reserved ABSTRACT Identification of the Binding Partners for HspB2 and CryAB Reveals Myofibril and Mitochondrial Protein Interactors and Non-Redundant Roles for Small Heat Shock Proteins Kelsey Langston Department of Microbiology and Molecular Biology, BYU Master of Science Small Heat Shock Proteins (sHSP) are molecular chaperones that play protective roles in cell survival and have been shown to possess chaperone activity.
    [Show full text]
  • Genetic Mutations and Mechanisms in Dilated Cardiomyopathy
    Genetic mutations and mechanisms in dilated cardiomyopathy Elizabeth M. McNally, … , Jessica R. Golbus, Megan J. Puckelwartz J Clin Invest. 2013;123(1):19-26. https://doi.org/10.1172/JCI62862. Review Series Genetic mutations account for a significant percentage of cardiomyopathies, which are a leading cause of congestive heart failure. In hypertrophic cardiomyopathy (HCM), cardiac output is limited by the thickened myocardium through impaired filling and outflow. Mutations in the genes encoding the thick filament components myosin heavy chain and myosin binding protein C (MYH7 and MYBPC3) together explain 75% of inherited HCMs, leading to the observation that HCM is a disease of the sarcomere. Many mutations are “private” or rare variants, often unique to families. In contrast, dilated cardiomyopathy (DCM) is far more genetically heterogeneous, with mutations in genes encoding cytoskeletal, nucleoskeletal, mitochondrial, and calcium-handling proteins. DCM is characterized by enlarged ventricular dimensions and impaired systolic and diastolic function. Private mutations account for most DCMs, with few hotspots or recurring mutations. More than 50 single genes are linked to inherited DCM, including many genes that also link to HCM. Relatively few clinical clues guide the diagnosis of inherited DCM, but emerging evidence supports the use of genetic testing to identify those patients at risk for faster disease progression, congestive heart failure, and arrhythmia. Find the latest version: https://jci.me/62862/pdf Review series Genetic mutations and mechanisms in dilated cardiomyopathy Elizabeth M. McNally, Jessica R. Golbus, and Megan J. Puckelwartz Department of Human Genetics, University of Chicago, Chicago, Illinois, USA. Genetic mutations account for a significant percentage of cardiomyopathies, which are a leading cause of conges- tive heart failure.
    [Show full text]
  • Unequal Allelic Expression of Wild-Type and Mutated B-Myosin in Familial Hypertrophic Cardiomyopathy
    Basic Res Cardiol (2011) 106:1041–1055 DOI 10.1007/s00395-011-0205-9 ORIGINAL CONTRIBUTION Unequal allelic expression of wild-type and mutated b-myosin in familial hypertrophic cardiomyopathy Snigdha Tripathi • Imke Schultz • Edgar Becker • Judith Montag • Bianca Borchert • Antonio Francino • Francisco Navarro-Lopez • Andreas Perrot • Cemil O¨ zcelik • Karl-Josef Osterziel • William J. McKenna • Bernhard Brenner • Theresia Kraft Received: 26 May 2011 / Revised: 29 June 2011 / Accepted: 7 July 2011 / Published online: 19 July 2011 Ó The Author(s) 2011. This article is published with open access at Springerlink.com Abstract Familial hypertrophic cardiomyopathy (FHC) genotyped and clinically well-characterized FHC patients is an autosomal dominant disease, which in about 30% of were analyzed. The fraction of mutated MYH7-mRNA in the patients is caused by missense mutations in one allele five patients with mutation R723G averaged to 66 and 68% of the b-myosin heavy chain (b-MHC) gene (MYH7). To of total MYH7-mRNA in soleus and myocardium, respec- address potential molecular mechanisms underlying the tively. For mutations I736T, R719W and V606M, fractions family-specific prognosis, we determined the relative of mutated MYH7-mRNA in M. soleus were 39, 57 and expression of mutant versus wild-type MYH7-mRNA. We 29%, respectively. For all mutations, unequal abundance found a hitherto unknown mutation-dependent unequal was similar at the protein level. Importantly, fractions of expression of mutant to wild-type MYH7-mRNA, which is mutated transcripts were comparable among siblings, in paralleled by similar unequal expression of b-MHC at the younger relatives and unrelated carriers of the same protein level.
    [Show full text]
  • Genome Editing for the Understanding and Treatment of Inherited Cardiomyopathies
    International Journal of Molecular Sciences Review Genome Editing for the Understanding and Treatment of Inherited Cardiomyopathies 1, 1, 1,2, Quynh Nguyen y , Kenji Rowel Q. Lim y and Toshifumi Yokota * 1 Department of Medical Genetics, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB T6G2H7, Canada; [email protected] (Q.N.); [email protected] (K.R.Q.L.) 2 The Friends of Garrett Cumming Research & Muscular Dystrophy Canada, HM Toupin Neurological Science Research Chair, Edmonton, AB T6G2H7, Canada * Correspondence: [email protected]; Tel.: +1-780-492-1102 These authors contributed equally to the work. y Received: 28 December 2019; Accepted: 19 January 2020; Published: 22 January 2020 Abstract: Cardiomyopathies are diseases of heart muscle, a significant percentage of which are genetic in origin. Cardiomyopathies can be classified as dilated, hypertrophic, restrictive, arrhythmogenic right ventricular or left ventricular non-compaction, although mixed morphologies are possible. A subset of neuromuscular disorders, notably Duchenne and Becker muscular dystrophies, are also characterized by cardiomyopathy aside from skeletal myopathy. The global burden of cardiomyopathies is certainly high, necessitating further research and novel therapies. Genome editing tools, which include zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs) and clustered regularly interspaced short palindromic repeats (CRISPR) systems have emerged as increasingly important technologies in studying
    [Show full text]
  • Novel Pathogenic Variants in Filamin C Identified in Pediatric Restrictive Cardiomyopathy
    Novel pathogenic variants in filamin C identified in pediatric restrictive cardiomyopathy Jeffrey Schubert1, 2, Muhammad Tariq3, Gabrielle Geddes4, Steven Kindel4, Erin M. Miller5, and Stephanie M. Ware2. 1 Department of Molecular Genetics, Microbiology, and Biochemistry, University of Cincinnati College of Medicine, Cincinnati, OH; 2 Departments of Pediatrics and Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN; 3 Faculty of Applied Medical Science, University of Tabuk, Tabuk, Kingdom of Saudi Arabia; 4Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI; 5Cincinnati Children’s Hospital Medical Center, Cincinnati, OH. Correspondence: Stephanie M. Ware, MD, PhD Department of Pediatrics Indiana University School of Medicine 1044 W. Walnut Street Indianapolis, IN 46202 Telephone: 317 274-8939 Email: [email protected] Grant Sponsor: The project was supported by the Children’s Cardiomyopathy Foundation (S.M.W.), an American Heart Association Established Investigator Award 13EIA13460001 (S.M.W.) and an AHA Postdoctoral Fellowship Award 12POST10370002 (M.T.). ___________________________________________________________________ This is the author's manuscript of the article published in final edited form as: Schubert, J., Tariq, M., Geddes, G., Kindel, S., Miller, E. M., & Ware, S. M. (2018). Novel pathogenic variants in filamin C identified in pediatric restrictive cardiomyopathy. Human Mutation, 0(ja). https://doi.org/10.1002/humu.23661 Abstract Restrictive cardiomyopathy (RCM) is a rare and distinct form of cardiomyopathy characterized by normal ventricular chamber dimensions, normal myocardial wall thickness, and preserved systolic function. The abnormal myocardium, however, demonstrates impaired relaxation. To date, dominant variants causing RCM have been reported in a small number of sarcomeric or cytoskeletal genes, but the genetic causes in a majority of cases remain unexplained especially in early childhood.
    [Show full text]
  • Hypertrophic Cardiomyopathy (HCM)
    case example: Hypertrophic Cardiomyopathy (HCM) who is the patient? • 24 year-old male with no cardiac symptoms; assessed due to family history • Normal ECG (no left ventricular hypertrophy or conduction disease), cardiac echocardiogram, cardiac MRI • No prior cardiovascular genetic testing what is the SCA 60 family history? • Family history of sudden cardiac arrest d.60 (SCA) and hypertrophic obstructive cardiomyopathy N • Father died at age 45 from SCA: HCM found on requested autopsy report No other SCA 45 reported d.45 • Paternal grandfather died at age 60 SCA HCM dx autopsy from SCA • No prior cardiovascular genetic testing - + done on family members MYH7 variant - 24 MYH7 variant + what happened with genetic testing? • Cardiologist ordered HCMFirst panel (MYH7 and MYBPC3 genes) with reflex option on patient (clinical rationale below): - Up to 50% of HCM due to a mutation in one of the HCMFirst genes, which represent ~80% of known genetic causes of HCM - Tiered approach: HCMFirst panel reflexes to larger HCMNext panel, only if needed • Positive finding: MYH7 variant, likely pathogenic: p.G584S • This alteration is reported in multiple patients with HCM.1,2,3 MYH7 mutations account for ~40% of HCM and 5-8% of dilated cardiomyopathy (DCM). MYH7 mutations can also cause left ventricular non-compaction (LVNC) and skeletal myopathies, with/ without cardiac involvement.4,5 how did genetic testing help the patient and family? • Confirmed patient to be at risk for HCM and sudden cardiac arrest, despite negative clinical presentation • Tiered
    [Show full text]
  • Cardiogenetics Testing Reference Guide December 2018
    Cardiogenetics Testing reference guide December 2018 Why Choose Ambry More than 1 in 200 people have an inherited cardiovascular condition. Ambry’s mission is to provide the most advanced genetic testing information available to help you identity those at-risk and determine the best treatment options. If we know a patient has a disease-causing genetic change, not only does it mean better disease management, it also indicates that we can test others in the family and provide them with potentially life-saving information. Diseases and Testing Options cardiomyopathies arrhythmias Hypertrophic Cardiomyopathy (HCMNext) Catecholaminergic Polymorphic Ventricular Dilated Cardiomyopathy (DCMNext) Tachycardia (CPVTNext) Arrhythmogenic Right Ventricular Long QT Syndrome, Short QT Syndrome, Cardiomyopathy (ARVCNext) Brugada Syndrome (LongQTNext, RhythmNext) Cardiomyopathies (CMNext, CardioNext) Arrhythmias (RhythmNext, CardioNext) other cardio conditions Transthyretin Amyloidosis (TTR) familial hypercholesterolemia Noonan Syndrome (NoonanNext) and lipid disorders Hereditary Hemorrhagic Telangiectasia Familial Hypercholesterolemia (FHNext) (HHTNext) Sitosterolemia (Sitosterolemia Panel) Comprehensive Lipid Menu thoracic aortic aneurysms (CustomNext-Cardio) and dissections Familial Chylomicronemia Syndrome (FCSNext) Thoracic Aneurysms and Dissections, aortopathies (TAADNext) Marfan Syndrome (TAADNext) Ehlers-Danlos Syndrome (TAADNext) Targeted Panels Gene Comparison ALL PANELS HAVE A TURNAROUND TIME OF 2-3 WEEKS arrhythmias CPVTNext CPVTNext CASQ2,
    [Show full text]
  • Microrna Regulatory Pathways in the Control of the Actin–Myosin Cytoskeleton
    cells Review MicroRNA Regulatory Pathways in the Control of the Actin–Myosin Cytoskeleton , , Karen Uray * y , Evelin Major and Beata Lontay * y Department of Medical Chemistry, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary; [email protected] * Correspondence: [email protected] (K.U.); [email protected] (B.L.); Tel.: +36-52-412345 (K.U. & B.L.) The authors contributed equally to the manuscript. y Received: 11 June 2020; Accepted: 7 July 2020; Published: 9 July 2020 Abstract: MicroRNAs (miRNAs) are key modulators of post-transcriptional gene regulation in a plethora of processes, including actin–myosin cytoskeleton dynamics. Recent evidence points to the widespread effects of miRNAs on actin–myosin cytoskeleton dynamics, either directly on the expression of actin and myosin genes or indirectly on the diverse signaling cascades modulating cytoskeletal arrangement. Furthermore, studies from various human models indicate that miRNAs contribute to the development of various human disorders. The potentially huge impact of miRNA-based mechanisms on cytoskeletal elements is just starting to be recognized. In this review, we summarize recent knowledge about the importance of microRNA modulation of the actin–myosin cytoskeleton affecting physiological processes, including cardiovascular function, hematopoiesis, podocyte physiology, and osteogenesis. Keywords: miRNA; actin; myosin; actin–myosin complex; Rho kinase; cancer; smooth muscle; hematopoiesis; stress fiber; gene expression; cardiovascular system; striated muscle; muscle cell differentiation; therapy 1. Introduction Actin–myosin interactions are the primary source of force generation in mammalian cells. Actin forms a cytoskeletal network and the myosin motor proteins pull actin filaments to produce contractile force. All eukaryotic cells contain an actin–myosin network inferring contractile properties to these cells.
    [Show full text]
  • MYL3 Monoclonal ANTIBODY Catalog Number:66286-1-Ig
    For Research Use Only MYL3 Monoclonal ANTIBODY www.ptglab.com Catalog Number:66286-1-Ig Catalog Number: GenBank Accession Number: Purification Method: Basic Information 66286-1-Ig BC009790 Protein G purification Size: GeneID (NCBI): CloneNo.: 150UL , Concentration: 1000 μg/ml by 4634 2E4B2 Bradford method using BSA as the Full Name: Recommended Dilutions: standard; myosin, light chain 3, alkali; WB 1:5000-1:50000 Source: ventricular, skeletal, slow IHC 1:20-1:200 Mouse Calculated MW: Isotype: 22 kDa IgG1 Observed MW: Immunogen Catalog Number: 22-25 kDa AG24535 Applications Tested Applications: Positive Controls: IHC, WB, ELISA WB : human skeletal muscle tissue, mouse heart tissue Species Specificity: IHC : human heart tissue, human skeletal muscle human, rat, mouse, pig tissue Note-IHC: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0 MYL3, also named as MLC1v, is an essential light chain of myosin that is associated with muscle contraction. It is Background Information expressed in ventricular and slow skeletal muscle. MYL3 may serve as a target for caspase-3 in dying cardiomyocytes. Mutations of MYL3 gene cause hypertrophic cardiomyopathy. MYL3 has been identified as potential serum biomarker for drug induced myotoxicity. Great increase in MYL3 serum concentration has been observed in rats with cardiac and skeletal muscle injury. (PMID:21685905) Storage: Storage Store at -20°C. Stable for one year after shipment. Storage Buffer: PBS with 0.02% sodium azide and 50% glycerol pH 7.3. Aliquoting is unnecessary for -20ºC storage For technical support and original validation data for this product please contact: This product is exclusively available under Proteintech T: 1 (888) 4PTGLAB (1-888-478-4522) (toll free E: [email protected] Group brand and is not available to purchase from any in USA), or 1(312) 455-8498 (outside USA) W: ptglab.com other manufacturer.
    [Show full text]
  • Sarcomeres Regulate Murine Cardiomyocyte Maturation Through MRTF-SRF Signaling
    Sarcomeres regulate murine cardiomyocyte maturation through MRTF-SRF signaling Yuxuan Guoa,1,2,3, Yangpo Caoa,1, Blake D. Jardina,1, Isha Sethia,b, Qing Maa, Behzad Moghadaszadehc, Emily C. Troianoc, Neil Mazumdara, Michael A. Trembleya, Eric M. Smalld, Guo-Cheng Yuanb, Alan H. Beggsc, and William T. Pua,e,2 aDepartment of Cardiology, Boston Children’s Hospital, Boston, MA 02115; bDepartment of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA 02215; cDivision of Genetics and Genomics, The Manton Center for Orphan Disease Research, Boston Children’s Hospital and Harvard Medical School, Boston, MA 02115; dAab Cardiovascular Research Institute, Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642; and eHarvard Stem Cell Institute, Harvard University, Cambridge, MA 02138 Edited by Janet Rossant, The Gairdner Foundation, Toronto, ON, Canada, and approved November 24, 2020 (received for review May 6, 2020) The paucity of knowledge about cardiomyocyte maturation is a Mechanisms that orchestrate ultrastructural and transcrip- major bottleneck in cardiac regenerative medicine. In develop- tional changes in cardiomyocyte maturation are beginning to ment, cardiomyocyte maturation is characterized by orchestrated emerge. Serum response factor (SRF) is a transcription factor that structural, transcriptional, and functional specializations that occur is essential for cardiomyocyte maturation (3). SRF directly acti- mainly at the perinatal stage. Sarcomeres are the key cytoskeletal vates key genes regulating sarcomere assembly, electrophysiology, structures that regulate the ultrastructural maturation of other and mitochondrial metabolism. This transcriptional regulation organelles, but whether sarcomeres modulate the signal trans- subsequently drives the proper morphogenesis of mature ultra- duction pathways that are essential for cardiomyocyte maturation structural features of myofibrils, T-tubules, and mitochondria.
    [Show full text]
  • Illuminating the Divergent Role of Filamin C Mutations in Human Cardiomyopathy
    Journal of Clinical Medicine Review Cardiac Filaminopathies: Illuminating the Divergent Role of Filamin C Mutations in Human Cardiomyopathy Matthias Eden 1,2 and Norbert Frey 1,2,* 1 Department of Internal Medicine III, University of Heidelberg, 69120 Heidelberg, Germany; [email protected] 2 German Centre for Cardiovascular Research, Partner Site Heidelberg, 69120 Heidelberg, Germany * Correspondence: [email protected] Abstract: Over the past decades, there has been tremendous progress in understanding genetic alterations that can result in different phenotypes of human cardiomyopathies. More than a thousand mutations in various genes have been identified, indicating that distinct genetic alterations, or combi- nations of genetic alterations, can cause either hypertrophic (HCM), dilated (DCM), restrictive (RCM), or arrhythmogenic cardiomyopathies (ARVC). Translation of these results from “bench to bedside” can potentially group affected patients according to their molecular etiology and identify subclinical individuals at high risk for developing cardiomyopathy or patients with overt phenotypes at high risk for cardiac deterioration or sudden cardiac death. These advances provide not only mechanistic insights into the earliest manifestations of cardiomyopathy, but such efforts also hold the promise that mutation-specific pathophysiology might result in novel “personalized” therapeutic possibilities. Recently, the FLNC gene encoding the sarcomeric protein filamin C has gained special interest since FLNC mutations were found in several distinct and possibly overlapping cardiomyopathy phenotypes. Specifically, mutations in FLNC were initially only linked to myofibrillar myopathy (MFM), but are now increasingly found in various forms of human cardiomyopathy. FLNC thereby Citation: Eden, M.; Frey, N. Cardiac represents another example for the complex genetic and phenotypic continuum of these diseases.
    [Show full text]
  • Transcriptomic Uniqueness and Commonality of the Ion Channels and Transporters in the Four Heart Chambers Sanda Iacobas1, Bogdan Amuzescu2 & Dumitru A
    www.nature.com/scientificreports OPEN Transcriptomic uniqueness and commonality of the ion channels and transporters in the four heart chambers Sanda Iacobas1, Bogdan Amuzescu2 & Dumitru A. Iacobas3,4* Myocardium transcriptomes of left and right atria and ventricles from four adult male C57Bl/6j mice were profled with Agilent microarrays to identify the diferences responsible for the distinct functional roles of the four heart chambers. Female mice were not investigated owing to their transcriptome dependence on the estrous cycle phase. Out of the quantifed 16,886 unigenes, 15.76% on the left side and 16.5% on the right side exhibited diferential expression between the atrium and the ventricle, while 5.8% of genes were diferently expressed between the two atria and only 1.2% between the two ventricles. The study revealed also chamber diferences in gene expression control and coordination. We analyzed ion channels and transporters, and genes within the cardiac muscle contraction, oxidative phosphorylation, glycolysis/gluconeogenesis, calcium and adrenergic signaling pathways. Interestingly, while expression of Ank2 oscillates in phase with all 27 quantifed binding partners in the left ventricle, the percentage of in-phase oscillating partners of Ank2 is 15% and 37% in the left and right atria and 74% in the right ventricle. The analysis indicated high interventricular synchrony of the ion channels expressions and the substantially lower synchrony between the two atria and between the atrium and the ventricle from the same side. Starting with crocodilians, the heart pumps the blood through the pulmonary circulation and the systemic cir- culation by the coordinated rhythmic contractions of its upper lef and right atria (LA, RA) and lower lef and right ventricles (LV, RV).
    [Show full text]